TBVAC2020: Advancing tuberculosis vaccines from discovery to clinical development
- Kaufmann, Stefan H. E.
- Dockrell, Hazel M.
- Drager, Nick
- Ho, Mei Mei
- McShane, Helen
- Neyrolles, Olivier
- Ottenhoff, Tom H. M.
- Patel, Brij
- Roordink, Danielle
- Spertini, François
- Stenger, Steffen
- Thole, Jelle
- Verreck, Frank A. W.
- Williams, Ann
- Britton, Warwick
- Triccas, Jamie
- Counoupas, Claudio
- Grooten, Johan
- Marie-Ange Demoitie, null
- Romano, Marta
- Huygen, Kris
- Tima, Hermann Giresse
- Mascart, Francoise
- Andersen, Peter
- Aagaard, Claus
- Christensen, Dennis
- Ruhwald, Morten
- Lindenstrom, Thomas
- Charneau, Pierre
- Guilhot, Christophe
- Peixoto, Antonio
- Gilleron, Martine
- Vergne, Isabelle
- Locht, Camille
- Brosch, Roland
- Inchauspe, Genevieve
- Theung Long, Stephane Leung
- Weiner, January
- Maertzdorf, Jeroen
- Nieuwenhuizen, Natalie
- Bastian, Max
- Kallert, Stephanie
- Gordon, Stephen
- Caccamo, Nadia
- Goletti, Delia
- Nisini, Roberto
- Shin, Sung Jae
- Cho, Sang Nae
- Lee, Hyejon
- Choi, Ino
- Sigal, Alex
- Scriba, Thomas
- Walzl, Gerhard
- Loxton, Andre
- Wilkinson, Robert
- Wilkinson, Katalin
- Cardona, Pere-Joan
- Vilaplana, Cris
- Martin, Carlos
- Marinova, Dessi
- Aguilo, Nacho
- Aebersold, Ruedi
- Caron, Etienne
- Pinschewer, Daniel
- De Libero, Gennaro
- Siegrist, Claire Anne
- Collin, Nicolas
- Barnier-Quer, Christophe
- Sander, Peter
- Sutherland, Jayne
- Verreck, Frank
- Ottenhoff, Tom
- Joosten, Simone
- Meijgaarden, Krista van
- Coppola, Mariateresa
- Geluk, Annemieke
- Perrie, Yvonne
- Baird, Marc
- Levin, Michael
- Kaforou, Myrsini
- Smith, Steven
- Fletcher, Helen
- Bancroft, Gregory
- Clark, Simon
- Sharpe, Sally
- Satti, Iman
- Stylianou, Elena
- Tanner, Rachel
- Vordermeier, Martin
- Hogarth, Philip
- Casimiro, Danilo
DOIAbstract
TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for ...
Add to ORKG